Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus

Key facts

Sponsor

Vifor Fresenius Medical Care Renal Pharma

Principal Investigator

Milica Enoiu, PhD, DDS

Vifor Pharma Group

Intervention

Difelikefalin Injection(drug)

Enrollment

260 enrolled

Eligibility

18-85 years · All sexes

Timeline

2023 – 2024

Study locations (30)

• Investigator Site 25, Baotou, China
• Investigator Site 01, Beijing, China
• Investigator Site 07, Beijing, China
• Investigator Site 26, Changsha, China
• Investigator Site 06, Guangzhou, China
• Investigator Site 12, Jiaxing, China
• Investigator Site 02, Lanzhou, China
• Investigator Site 34, Mianyang, China
• Investigator Site 03, Nanjing, China
• Investigator Site 10, Nanjing, China
• Investigator Site 19, Nanjing, China
• Investigator Site 36, Nantong, China
• Investigator Site 40, Shanghai, China
• Investigator Site 18, Shenyang, China
• Investigator Site 21, Shenyang, China
• +15 more locations on ClinicalTrials.gov

Collaborators

Tigermed Consulting Co., Ltd

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Uremic pruritus

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT06446310
  Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
  Qilu Pharmaceutical (Hainan) Co., Ltd.

See all trials for Uremic pruritus →